News

MNM Bioscience announced that it had filed a provisional patent application

Date
June 2, 2022
No items found.

MNM Bioscience announced that it had filed a provisional patent application

RSF determines tumor drug responsiveness and provides a response score for patient treatment with defective DNA damage repair mechanisms. The patented method is clinically significant, as malfunctions in DNA damage repair dramatically increase genome instability, a hallmark of most cancers.

Consistently, the RSF method predicts treatment responsiveness in multiple cancer types for multiple DNA damaging agents, such as PARP and CDK4/6 inhibitors. RSF is a classification algorithm that uses whole-genome sequencing (WGS) data to detect complex genomic biomarkers based on a distance-based projection.

The process of training an RSF is as follows:

-variant* type selection (e.g., copy number alterations, deletions or insertions, structural variants: duplications or translocations),

-histogram-based features extraction (calculation of frequencies and densities of variant types),

-Random Similarity Forest classifier training (which performs a distance projection of variant distributions).

Inside, RSF combines the properties of other AI algorithms, namely Random Forests and Similarity Forests. As a result, RSF is capable of learning from simple numeric data (e.g., gene amplifications) and complex data (e.g., structural variant distributions) at the same time. RSF’s data flexibility allows it to process different data types and, therefore, all the modalities WGS data can offer.

MNM Bioscience announced that it had filed a provisional patent application
June 15, 2022

You may also like

MNM Bioscience joins ESMO Breast Cancer 2022

Breast cancer (BC) constitutes the most common female malignancy and nowadays molecular classification of subtypes is crucial to estimate a patient’s prognosis and administer appropriate treatment. It allows tailoring therapeutic strategy much more precisely than using a standalone IHC status.

“Random similarity forests” has been accepted at ECML PKDD 2022

We are very happy to announce that our abstract and related publication titled “Random similarity forests” has been accepted at this year’s European Conference on Machine Learning and Principles and Practice of Knowledge Discovery in Databases- #ECMLPKDD2022!

MNM Bioscience announced that it had filed a provisional patent application

MNM Bioscience announced that it had filed a provisional patent application

Our latest Nature Immunology article has been just released

In the Perspective work-issued today, we highlight the possible genetic background of COVID-19 interindividual variability, ranging from asymptomatic infection to life-threatening disease.